Braveheart Investment Group PLC on investors’ radar as coronavirus

Braveheart Investment Group PLC (AIM:BRH) provided an update on PhaseFocus Holdings Limited, a company in which it owns a 42.6% stake, as it plans to expand production facilities in early 2022 to meet anticipated demand.

PhaseFocus, which has developed a series of imaging techniques with a range of applications including live cell imaging, engineering metrology and electron microscopy, has signed a distribution agreement with Swedish bio-convergence company BICO Group.

Braveheart said this deal has given the Nottingham-based business an “excellent platform for driving sales growth across the EU and USA”.

Braveheart said that BICO’s CYTENA arm is promoting Livecyte, PhaseFocus’ label free content system very strongly, with three Livecyte cell imaging systems to be shipped to CYTENA to be distributed to centres in the EU and US.